Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 9/20 | 0.46 |
| ▸ | HRH1 | P35367 | 8/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.46 |
| ▸ | DRD3 | P35462 | 6/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | HTR1A | P08908 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5902888 | 0.99 | SLC6A2 (0.47) | HTR2BHRH1SLC6A2KCNH2CHRM2 | |
| SCHEMBL20773893 | 0.83 | LMNA (0.45) | HTR2BHRH1SLC6A2KCNH2CHRM2 | |
| SCHEMBL9421101 | 0.73 | — | — | |
| SCHEMBL9421106 | 0.73 | — | — | |
| SCHEMBL1235245 | 0.71 | CYP1A2 (0.31) | CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL9421065 | 0.70 | — | — | |
| SCHEMBL4913656 | 0.66 | HRH1 (0.44) | HTR2BHRH1SLC6A2KCNH2CHRM2 | |
| SCHEMBL2747705 | 0.64 | HDAC1 (0.42) | LMNAALDH1A1 | |
| Amitriptyline SCHEMBL2877708 | 0.63 | SLC6A2 (1.00) | HTR2BHRH1SLC6A2KCNH2CHRM2 | |
| Amitriptyline SCHEMBL29359365 | 0.63 | SLC6A2 (1.00) | HTR2BHRH1SLC6A2KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675814-A1 | COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES | Bläss, Markus (DE) | 2020-07-08 | — | — | EP | claimed |
| WO-2019043064-A1 | COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES | BLAESS MARKUS (DE) | 2019-03-07 | — | — | WO | claimed |
| US-20210308120-A1 | Use of Amitriptyline for Blocking Brain Hemichannels and Method for Potentiating its Effect in Vivo | THERANEXUS (FR) | 2021-10-07 | — | — | US | disclosed |
| EP-3322412-B1 | USE OF AMITRIPTYLINE FOR BLOCKING BRAIN HEMICHANNELS AND METHOD FOR POTENTIATING ITS EFFECT IN VIVO | THERANEXUS (FR) | 2021-04-07 | — | — | EP | disclosed |
| EP-3675814-A1 | COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES | Bläss, Markus (DE) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019043064-A1 | COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES | BLAESS MARKUS (DE) | 2019-03-07 | — | — | WO | disclosed |
| US-20180207147-A1 | USE OF AMITRIPTYLINE FOR BLOCKING BRAIN HEMICHANNELS AND METHOD FOR POTENTIATING ITS EFFECT IN VIVO | THERANEXUS (FR) | 2018-07-26 | — | — | US | disclosed |
| EP-1397145-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | Müller, Norbert (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002102297-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | MUELLER NORBERT (DE) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207147-A1 | USE OF AMITRIPTYLINE FOR BLOCKING BRAIN HEMICHANNELS AND METHOD FOR POTENTIATING ITS EFFECT IN VIVO | GAP43, GJB2, HCN3 | HTR2B 26/4885HRH1 541/4885SLC6A2 25/4885 |
| US-20210308120-A1 | Use of Amitriptyline for Blocking Brain Hemichannels and Method for Potentiating its Effect in Vivo | GAP43, GJB2, HCN3 | HTR2B 26/4885HRH1 541/4885SLC6A2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.